MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• MET fusions are infrequently identified oncogenic drivers in non-small cell lung cancer (NSCLC).
• Limited data exists on patient characteristics and treatment outcomes for MET fusion-positive NSCLC.
• Understanding these rare events is crucial for targeted therapy development.

Purpose of the Study:

• To characterize histopathologic features, patient demographics, and treatment responses in MET fusion-positive NSCLC.
• To evaluate the efficacy of MET tyrosine kinase inhibitor (TKI) therapy in this patient cohort.
• To determine the frequency and molecular heterogeneity of MET fusions in NSCLC.

Main Methods:

• Identification of NSCLC patients with MET fusions via routine RNA sequencing.
• Retrospective analysis of clinical data, including histopathology and demographics.
• Assessment of treatment response to MET TKI therapy and analysis of resistance mechanisms.

Main Results:

• A cohort of nine MET fusion-positive NSCLC patients was identified, with a frequency of 0.29%.
• All identified tumors were adenocarcinomas, exhibiting heterogeneity in fusion partners and breakpoints.
• Four patients treated with MET TKI showed two partial responses and one stable disease; one developed acquired resistance via BRAF V600E mutation.

Conclusions:

• MET fusions are rare, heterogeneous driver events in NSCLC, predominantly found in adenocarcinomas.
• Patients with MET fusion-positive NSCLC can potentially benefit from MET TKI treatment.
• Further research is warranted to explore optimal therapeutic strategies for this rare subset of NSCLC.